Drugs / A2/4-1BBL melanoma vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT01861938 | Mar 2017 → Mar 2019 | metastatic neoplasm | Hadassah Medical Organization | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A2/4-1BBL melanoma vaccine | “the A2/4-1BBL melanoma vaccine, a compatible melanoma cell line” NCT01861938 ↗ |
| Modality | Vaccine | “modified tumor cell vaccine” NCT01861938 ↗ |